Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Prostacyclin and Prostacyclin Analogs
1.2.3 SGC Stimulators
1.2.4 ERA
1.2.5 PDE-5
1.3 Market by Application
1.3.1 Global Pulmonary Arterial Hypertension (PAH) Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2018-2033)
2.2 Pulmonary Arterial Hypertension (PAH) Growth Trends by Region
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Size by Region (2018-2023)
2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2024-2033)
2.3 Pulmonary Arterial Hypertension (PAH) Market Dynamics
2.3.1 Pulmonary Arterial Hypertension (PAH) Industry Trends
2.3.2 Pulmonary Arterial Hypertension (PAH) Market Drivers
2.3.3 Pulmonary Arterial Hypertension (PAH) Market Challenges
2.3.4 Pulmonary Arterial Hypertension (PAH) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue
3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2018-2023)
3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2018-2023)
3.2 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
3.4 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
3.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2022
3.5 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
3.6 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
3.7 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Type
4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2018-2023)
4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2024-2033)
5 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Application
5.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Application (2018-2023)
5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2018-2033)
6.2 North America Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023)
6.4 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2018-2033)
7.2 Europe Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023)
7.4 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size (2018-2033)
8.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2023)
8.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size (2018-2033)
9.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023)
9.4 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size (2018-2033)
10.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023)
10.4 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Actelion
11.1.1 Actelion Company Detail
11.1.2 Actelion Business Overview
11.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
11.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
11.1.5 Actelion Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
11.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 United Therapeutics
11.3.1 United Therapeutics Company Detail
11.3.2 United Therapeutics Business Overview
11.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
11.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
11.3.5 United Therapeutics Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
11.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
11.4.5 GlaxoSmithKline Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
11.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Bayer
11.6.1 Bayer Company Detail
11.6.2 Bayer Business Overview
11.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
11.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
11.6.5 Bayer Recent Development
11.7 Arena
11.7.1 Arena Company Detail
11.7.2 Arena Business Overview
11.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
11.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
11.7.5 Arena Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Prostacyclin and Prostacyclin Analogs
Table 3. Key Players of SGC Stimulators
Table 4. Key Players of ERA
Table 5. Key Players of PDE-5
Table 6. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region (2018-2023)
Table 10. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region (2024-2033)
Table 12. Pulmonary Arterial Hypertension (PAH) Market Trends
Table 13. Pulmonary Arterial Hypertension (PAH) Market Drivers
Table 14. Pulmonary Arterial Hypertension (PAH) Market Challenges
Table 15. Pulmonary Arterial Hypertension (PAH) Market Restraints
Table 16. Global Pulmonary Arterial Hypertension (PAH) Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players (2018-2023)
Table 18. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2022)
Table 19. Ranking of Global Top Pulmonary Arterial Hypertension (PAH) Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
Table 23. Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Pulmonary Arterial Hypertension (PAH) Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2018-2023)
Table 27. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2024-2033)
Table 29. Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2018-2023)
Table 31. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2024-2033)
Table 33. North America Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2024-2033) & (US$ Million)
Table 48. Actelion Company Detail
Table 49. Actelion Business Overview
Table 50. Actelion Pulmonary Arterial Hypertension (PAH) Product
Table 51. Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023) & (US$ Million)
Table 52. Actelion Recent Development
Table 53. Gilead Sciences Company Detail
Table 54. Gilead Sciences Business Overview
Table 55. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product
Table 56. Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023) & (US$ Million)
Table 57. Gilead Sciences Recent Development
Table 58. United Therapeutics Company Detail
Table 59. United Therapeutics Business Overview
Table 60. United Therapeutics Pulmonary Arterial Hypertension (PAH) Product
Table 61. United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023) & (US$ Million)
Table 62. United Therapeutics Recent Development
Table 63. GlaxoSmithKline Company Detail
Table 64. GlaxoSmithKline Business Overview
Table 65. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Product
Table 66. GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023) & (US$ Million)
Table 67. GlaxoSmithKline Recent Development
Table 68. Pfizer Company Detail
Table 69. Pfizer Business Overview
Table 70. Pfizer Pulmonary Arterial Hypertension (PAH) Product
Table 71. Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023) & (US$ Million)
Table 72. Pfizer Recent Development
Table 73. Bayer Company Detail
Table 74. Bayer Business Overview
Table 75. Bayer Pulmonary Arterial Hypertension (PAH) Product
Table 76. Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023) & (US$ Million)
Table 77. Bayer Recent Development
Table 78. Arena Company Detail
Table 79. Arena Business Overview
Table 80. Arena Pulmonary Arterial Hypertension (PAH) Product
Table 81. Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2018-2023) & (US$ Million)
Table 82. Arena Recent Development
Table 83. Research Programs/Design for This Report
Table 84. Key Data Information from Secondary Sources
Table 85. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pulmonary Arterial Hypertension (PAH) Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Market Share by Type: 2022 VS 2033
Figure 3. Prostacyclin and Prostacyclin Analogs Features
Figure 4. SGC Stimulators Features
Figure 5. ERA Features
Figure 6. PDE-5 Features
Figure 7. Global Pulmonary Arterial Hypertension (PAH) Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2022 VS 2033
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Pulmonary Arterial Hypertension (PAH) Report Years Considered
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region: 2022 VS 2033
Figure 15. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players in 2022
Figure 16. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue in 2022
Figure 18. North America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2018-2033)
Figure 20. United States Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Canada Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Country (2018-2033)
Figure 24. Germany Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. France Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. U.K. Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Italy Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Russia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Nordic Countries Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Region (2018-2033)
Figure 32. China Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Japan Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. South Korea Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. India Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Australia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2018-2033)
Figure 40. Mexico Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Brazil Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Country (2018-2033)
Figure 44. Turkey Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Actelion Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
Figure 47. Gilead Sciences Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
Figure 48. United Therapeutics Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
Figure 49. GlaxoSmithKline Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
Figure 50. Pfizer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
Figure 51. Bayer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
Figure 52. Arena Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2018-2023)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed